Thus, the clinical response to anti-PD-1 treatment in GBM is associated with specific molecular patterns and clonal evolution during treatment, lack of which develops an acquired resistant state in the glioma tumor, thus resulting in therapy failure [24,147]. Here, PDCD1 is linked to central nervous system cancer.